iCAD, Inc. (NASDAQ:ICAD – Get Rating) has been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $12.50.
Separately, BTIG Research dropped their price objective on shares of iCAD from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, June 24th.
Hedge Funds Weigh In On iCAD
Large investors have recently added to or reduced their stakes in the company. Oak Family Advisors LLC increased its holdings in shares of iCAD by 15.4% during the second quarter. Oak Family Advisors LLC now owns 106,503 shares of the technology company’s stock valued at $426,000 after acquiring an additional 14,205 shares in the last quarter. Walleye Capital LLC increased its holdings in shares of iCAD by 38.6% during the first quarter. Walleye Capital LLC now owns 183,215 shares of the technology company’s stock valued at $817,000 after acquiring an additional 51,071 shares in the last quarter. Portolan Capital Management LLC acquired a new position in shares of iCAD during the first quarter valued at about $4,041,000. Engineers Gate Manager LP increased its holdings in shares of iCAD by 93.5% during the first quarter. Engineers Gate Manager LP now owns 82,394 shares of the technology company’s stock valued at $367,000 after acquiring an additional 39,815 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of iCAD by 31.3% during the first quarter. Renaissance Technologies LLC now owns 356,390 shares of the technology company’s stock valued at $1,589,000 after acquiring an additional 84,900 shares in the last quarter. 48.53% of the stock is currently owned by institutional investors.
iCAD Price Performance
iCAD (NASDAQ:ICAD – Get Rating) last announced its quarterly earnings results on Wednesday, May 11th. The technology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.04). iCAD had a negative return on equity of 26.45% and a negative net margin of 40.43%. The business had revenue of $7.52 million during the quarter, compared to the consensus estimate of $7.50 million. As a group, equities analysts expect that iCAD will post -0.57 EPS for the current year.
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment.
- Get a free copy of the StockNews.com research report on iCAD (ICAD)
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- There Are Different Types of Stock To Invest In
- Is Starbucks Shooting For The Moon?
- Two High-Yield Deep-Values You Shouldn’t Ignore
- PayPal Continues To Struggle As Competition Increases
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.